Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.57 per share in its upcoming report, which indicates a year-over-year increase of 3.6%. Revenues are expected to be ...

"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...

AstraZeneca reported positive Phase III results for tozorakimab in COPD, meeting the primary endpoint with clinically ...

April 21 () - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met ‌the main goal of a late-stage trial ...

AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

AstraZeneca PLC has announced that Rene Haas will step down as a Non-Executive Director on April 30, 2026. Haas has been appointed as the Chief Executive Officer of SoftBank Group International. This ...

A global drug company which pioneered the Covid vaccine has been victim of a cyber attack, Metro can reveal. AstraZeneca was ...

Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...

AstraZeneca PLC announced the successful completion of Phase III trials for Ultomiris, achieving the primary endpoint by ...

An important update about the superfund-qualified Zeneca Site was given to local residents on April 9, concerning the ...

In an exclusive interview, the architect behind the Stirling Prize-shortlisted Wraxall Yard talks to Tom Lowe about why ...